Figure 7.

No-alpha mutein maintains the long-lasting protection conferred by the anti-CD20 mAb. Induction of CD8⁺ TCM cells (a) and CD8⁺ TEM cells (b) in the peripheral blood of mice injected with 2 × 10⁵ EL4-huCD20 tumor cells and treated with anti-CD20 + no-alpha mutein measured by flow cytometry, at day 21 after tumor injection. Horizontal bars represent the mean ± SD of percentages and the dotted lines represent the mean value obtained with isotype control-treated C57Bl/6 mice for the indicated population. Data correspond to two independent experiments (n = 5–10 per group) (Kruskal-Wallis, Dunn’s post hoc test, *, P < .05; **, P < .01; ***, P < .001; ns: not significant). (c), Schematic representation of treatment schedule. (d), No-alpha mutein maintained the long-term protection conferred by anti-CD20 therapy when surviving animals were rechallenged with tumor cells. Age-matched naïve mice were injected with equal number of cells and used as controls (n = 5 per control group). Data correspond to two independent experiments (log-rank test; *, P < .05; ***, P < .001; ns: not significant).